本文選題：肺血管擴(kuò)張劑 + 肺動(dòng)脈高壓　； 參考：《中華高血壓雜志》2017年04期

【摘要】：正肺動(dòng)脈高壓(pulmonary arterial hypertension,PAH)患者使用肺血管擴(kuò)張劑發(fā)生藥物不良反應(yīng)(adverse drug events,ADEs)很常見。ADEs可能導(dǎo)致生活質(zhì)量下降;然而,它們與預(yù)后的關(guān)系未知。該研究的目的是確定開始皮下曲前列環(huán)素治療后常見的ADEs是否與PAH的預(yù)后相關(guān)。方法:納入來(lái)自4個(gè)PAH曲前列環(huán)素臨床試驗(yàn)的受試者進(jìn)行回顧性隊(duì)列研究,其中
[Abstract]:Adverse drug reactions with pulmonary vasodilator may lead to a decline in quality of life (QOL) in patients with pulmonary arterial hypertensioning. However, the relationship between ADEs and prognosis is unknown. The aim of this study was to determine whether common ADEs after subcutaneous triprostacyclin therapy was associated with the prognosis of PAH. Methods: a retrospective cohort study was conducted in four subjects from four PAH triprostacyclin clinical trials.
【分類號(hào)】：R544.1
，

本文編號(hào)：1826489